BPDCN is an aggressive type of blood cancer that originates from plasmacytoid dendritic cells (pDCs), a component of the immune system that produces type 1 interferon cytokines. These cytokines ...

Patients with blood cancers like polycythemia vera, a kind of myeloproliferative neoplasm, may benefit in learning more about ...

During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with ...

Patients with blastic plasmacytoid dendritic cell neoplasms can enroll in the ongoing CADENZA trial, which is investigating the safety and efficacy of the novel agent pivekimab sunirine in patients ...

including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia and acute lymphocytic leukemia. BPDCN — a rare but aggressive blood cancer — has features of both ...

A multi-institutional clinical trial has given good results for a targeted therapy to treat a rare, aggressive blood cancer known as blastic plasmacytoid dendritic-cell neoplasm (BPDCN).

No writing assistance was utilized in the production of this manuscript. Plasmacytoid dendritic cells (pDCs) are specialized APCs. Compared with other APCs, pDCs express a high level of TLR9 and ...

Dendritic cells (DC ... and express myeloid-specific markers. Plasmacytoid DCs resemble plasma cells and do not express myeloid markers. Their primary role is thought to be in response to viral ...

Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive hematologic cancer that is caused by transformed plasmacytoid dendritic cells that overexpress interleukin-3 receptor subunit ...